Death toll rises to 45 in Sigachi Industries explosion in Hyderabad
The deceased was identified as 45-year-old Tarak from West Bengal, who suffered over 75% burn injuries in the June 30 explosion that ripped through the dryer unit of the firm located in Pashamylaram of Sangareddy district. Arrangements were made by district authorities to send the deceased's body to his native place. Currently, four more patients are undergoing treatment at the same hospital, with one of them, Rajesh Kumar Chowdary (42) from Bihar, being on a non-invasive ventilator (HIV).
The condition of the other three is stable, according to doctors.
Meanwhile, another two victims, Videshi Kahar (48) and Ganga Mukhiya (38), both of whom suffered from 40% burns, were declared stable and were discharged from another private hospital in Patancheru on Monday. Eight people are still untraced from the incident.
You Can Also Check:
Hyderabad AQI
|
Weather in Hyderabad
|
Bank Holidays in Hyderabad
|
Public Holidays in Hyderabad
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
New Indian Express
7 hours ago
- New Indian Express
HIV prevention: Gilead's vaccine breakthrough nears EU approval
CHENNAI: Gilead Sciences has achieved another milestone in its efforts to bring in a preventive drug to curb the still rapidly spreading HIV epidemic, in the world with the European Medicines Agency's (EMA) advisory committee issuing a positive opinion for its twice-yearly injectable, lenacapavir. EMA the decision on Thursday (July 24) clears the way for approval by the European Commission later this year, following similar regulatory clearance in the United States in June 2025. Lenacapavir, a HIV pre-exposure prophylaxis (PrEP), is to be marketed in Europe under the brand name Yeytuo, is a long-acting injectable designed to prevent HIV infection with just two subcutaneous doses annually, following an initial oral lead-in. This innovative therapy is part of a new class of HIV-1 capsid inhibitors that disrupt multiple stages of the viral replication cycle. It represents the first and only twice-yearly PrEP option for individuals at risk of HIV, offering a significant alternative to the currently available daily oral pills like Truvada (TDF/FTC). Clinical trials have demonstrated strong efficacy. In the PURPOSE 1 trial, conducted among over 5,000 cisgender women and adolescent girls in South Africa and Uganda, lenacapavir achieved 100% efficacy—zero new HIV infections were reported in the treatment group. A second trial, PURPOSE 2, involving a broader group of cisgender men, transgender, and non-binary adults, showed a 96% reduction in HIV risk compared to those on daily PrEP. These results prompted early unblinding of both trials due to overwhelming benefit. Participants also reported high satisfaction with the twice-yearly regimen, citing ease of adherence, reduced stigma, and fewer missed doses compared to daily pills. Gilead's chief medical officer, Dr. Dietmar Berger, was on Friday quoted in reports saying that lenacapavir 'has the potential to become a critical tool for public health,' especially for individuals who face barriers to consistent healthcare access. The product is expected to play a vital role in addressing rising HIV infections in Europe, where more than 24,700 new diagnoses were reported in 2023—an 11.8% increase from the previous year across the EU, Iceland, Liechtenstein, and Norway. Beyond Europe, Gilead is pursuing a global access strategy for lenacapavir. The company has licensed the drug for generic production in 120 low-and lower-middle-income countries and is working toward WHO prequalification and inclusion in international HIV prevention guidelines. It is also eligible for EU-M4all procedures, which would streamline regulatory pathways for resource-limited settings.
NDTV
9 hours ago
- NDTV
Girl With HIV Raped, Forced To Abort At Maharashtra Children's Home
Latur: An HIV-infected girl has alleged that she was raped for two years at a children's shelter in Maharashtra's Latur and was forced to undergo an abortion. In her police complaint, the 16-year-old said that she was raped by an employee four times between July 13, 2023 and July 23 this year at Sevalay, a shelter home for HIV-infected children. She was taken to a hospital after she fell ill, where tests revealed that she was four months pregnant. The accused then got a doctor who performed an abortion procedure without her consent, the news agency PTI reported, citing an official. "She was also threatened not to disclose the ordeal to anyone," the official said. The girl then wrote a letter to officials and dropped it into a complaint box. The institution's management, however, did not help her and tore up the letter, the official said. Sevalay's founder, Ravi Bapatle, superintendent, Rachna Bapatle, and employees Amit Mahamuni and Pooja Waghmare are among those arrested. Sevalay, whose tagline is a "happy home of children", houses 23 boys and seven girls, all of whom are HIV infected, according to its website. All the workers in the institution work for free, the website said.
Indian Express
9 hours ago
- Indian Express
Maharashtra boosts support for TB control through private sector partnership
The Maharashtra government has stepped up its support for patient provider support agencies (PPSA) to help find and treat more tuberculosis patients as part of the national strategy to eliminate the disease. PPSA is a model where a non-governmental organisation/third-party agency is selected by the state/city/district unit of the National TB Elimination Programme (NTEP) to engage private-sector doctors. The agencies engage with private practitioners to ensure delivery of standardised TB care services. This effort has been successful in improving TB case detection and treatment outcomes, according to officials. 'Engaging the private sector is a vital element of the NTEP. To support this effort, the state has extended its support to more PPSAs. In the last six months (January till June), over half of the 1.13 lakh new TB cases have been reported from the private sector,' Dr Sandeep Sangale, joint director (TB and leprosy), Maharashtra, told The Indian Express. Dr Sangale explained that these agencies serve as a bridge between the state/district NTEP and the private healthcare sector and ensure that patients in private care have access to NTEP-supported services. Currently, PPSA is functional in 80 NTEP districts through seven agencies: Maharashtra Janvikas Kendra (MJK), ALERT India, Doctors for You (DFY), Gurukrupa Vikas Sanstha, DISHA foundation, Hindustan Latex Family Planning Promotion Trust (HLFPPT) and Network of Maharashtra by People living with AIDS/HIV (NMP+). Study shows evidence for public-private partnerships in TB elimination Given that nearly half of TB patients seek care from private providers, a new study shows well-funded public-private partnerships are no longer an option but essential for TB elimination goals. Published in the Indian Journal of Tuberculosis, the study provides compelling evidence for the effectiveness of this model based on a decade-long analysis of Maharashtra's TB programme (2011-2020). The study, published by researchers Ajith Ramalingam, Ranjit Mankeshwar, and Geeta Pardeshi, demonstrates how the effective utilisation of the National Health Mission (NHM) has directly improved TB outcomes in Maharashtra. The findings demonstrate that higher utilisation of funds—particularly in key operational areas such as supervision, public–private partnerships, and contractual services—is strongly associated with improved TB outcome indicators, increased case notification, treatment success rates and reduced case fatality rates. 'The analysis of NHM funds for the NTEP in Maharashtra from 2011 to 2020 revealed a consistent increase in both the allocation and utilisation of funds over the decade, with significant peaks observed in 2019 and 2020,' researchers said. In Maharashtra, the programme achieved its strongest outcomes when public-private partnerships were well-funded, with public–private mix (PPM) components showing a high median utilisation of 85.25 per cent, among the best across all programme areas. Central to this success was the PPSA model, backed by steadily rising contractual services funding over the decade, they added. Anuradha Mascarenhas is a journalist with The Indian Express and is based in Pune. A senior editor, Anuradha writes on health, research developments in the field of science and environment and takes keen interest in covering women's issues. With a career spanning over 25 years, Anuradha has also led teams and often coordinated the edition. ... Read More
